Announcement on Correction of Report for Q3 2024
Filed with SSE · · 2 pages · Chinese
Yabao Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Yabao Pharmaceutical
- Report for Q3 2024
- Announcement on Obtaining Approval of Phase II Clinical Trial for New Indication of Project SY-009
- Announcement on Notice to Creditors
- Announcement on Convening 2024 Semi-annual Performance Briefing
- Announcement on Resolutions of the 6th Meeting of the 9th Board of Directors
Later from Yabao Pharmaceutical
- Announcement on Convening the Q3 2024 Performance Briefing
- Announcement on a Wholly-owned Subsidiary Obtaining One Drug Registration Certificate
- Announcement on the Termination of the Technology Transfer Agreement for the Traditional Chinese Medicine New Drug Project
- Announcement on the Repurchased Company Shares Reaching 1% and Repurchase Progress
- Announcement on ZY-A001 Obtaining Notice of Approval for Drug Clinical Trials
Follow Yabao Pharmaceutical into a list and get an email when it puts out news.
Follow Yabao Pharmaceutical